Gastrointestinal Diseases Drug Development Pipeline Review, 2018: Gastroenteritis, Enterocolitis, Gastritis and Peritonitis - ResearchAndMarkets.com
Friday, 11 January 2019 00:06
Jan. 11, 2019 10:47 UTC

Gastrointestinal Diseases Drug Development Pipeline Review, 2018: Gastroenteritis, Enterocolitis, Gastritis and Peritonitis - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)-- The "Gastrointestinal Diseases Drug Development Pipeline Review 2018" report has been added to ResearchAndMarkets.com's offering.

Gastrointestinal Diseases Drug Development Pipeline Review, 2018 provides an overview of the pipeline landscape for gastrointestinal diseases.

It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for gastroenteritis, enterocolitis, gastritis and peritonitis, and features dormant and discontinued products.

  • Gastroenteritis: There are 12 products in development for this indication.
  • Enterocolitis: There are 8 products in development for this indication.
  • Gastritis: There are 11 products in development for this indication.
  • Peritonitis: There are 7 products in development for this indication.

Molecular targets in development for gastrointestinal diseases include toll-like receptors, interleukin receptors and bacterial proteins. Companies operating in this pipeline space include Kyowa Hakko Kirin, RedHill Biopharma and GlaxoSmithKline.

Scope

  • Which companies are the most active within each pipeline?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in this disease area?

Topics Covered

1 Table of Contents

2 Introduction

3 Therapeutics Development

4 Therapeutics Assessment

5 Companies Involved in Therapeutics Development

6 Dormant Projects

7 Discontinued Products

8 Product Development Milestones

Companies Profiled

  • Avexegen Therapeutics Inc
  • BCWorld Pharm Co Ltd
  • Daewon Pharm Co Ltd
  • Daewoong Pharmaceutical Co Ltd
  • GlaxoSmithKline Plc
  • Infant Bacterial Therapeutics AB
  • Kyowa Hakko Kirin Co Ltd
  • Leadiant Biosciences Inc
  • Medicago Inc
  • Nosopharm SAS
  • Ology Bioservices Inc
  • Oncodesign SA
  • ProMetic Life Sciences Inc
  • Recce Ltd
  • RedHill Biopharma Ltd
  • Regeneron Pharmaceuticals Inc
  • Sequella Inc
  • SynAct Pharma AB
  • Takeda Pharmaceutical Co Ltd
  • UMN Pharma Inc
  • Vaxart Inc

For more information about this report visit https://www.researchandmarkets.com/research/vjw5x7/gastrointestinal?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Drug Discovery, Gastrointestinal Drugs


Source: Research and Markets




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
 

Newsletter